Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab PK/PD in Moderate to Severe COVID-19 Pneumonia (MARIPOSA)
NCT04363736Phase 2Completed
- Sponsor
- Roche
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in COVID-19 pneumonia, sponsored by Roche. Started May 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04363736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363736.